Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Bladder cancer is the second most common genitourinary malignancy, with 81,190 estimated new diagnoses in 2018, in the United States alone. Transurethral resection of the bladder and radical cystectomy with bilateral pelvic lymph node dissection constitute the standard treatment for non-muscle invasive or very high-risk non-muscle invasive bladder cancer, respectively. However, survival expectations have not shown to improve in the last 20 years, and new diagnostic and therapeutic tools are urgently needed to improve the outcomes of this potentially lethal disease.

Medicine --- bladder cancer --- robotic-assisted --- open --- radical cystectomy --- survival --- propensity score --- age --- urothelial carcinoma --- outcome --- anesthesia recovery periods --- cognitive impairment --- gamma-cyclodextrins --- neuromuscular blockade --- robotic radical cystectomy --- glycogen --- clear-cell adenocarcinoma --- urinary bladder --- SEER program database --- female --- intracorporeal neobladder --- outcomes --- robotic --- sex-sparing --- methylation --- biomarkers --- FOXA1 --- GATA3 --- KRT20 --- molecular markers --- mRNA --- muscle-invasive bladder cancer --- PCR --- human epidermal growth factor receptor 2 --- indoleamine 2,3-dioxygenase --- programmed death ligand-1 --- immunotherapy --- nodal disease --- pN1 --- neoadjuvant --- adjuvant --- chemotherapy --- n/a

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Bladder cancer is the second most common genitourinary malignancy, with 81,190 estimated new diagnoses in 2018, in the United States alone. Transurethral resection of the bladder and radical cystectomy with bilateral pelvic lymph node dissection constitute the standard treatment for non-muscle invasive or very high-risk non-muscle invasive bladder cancer, respectively. However, survival expectations have not shown to improve in the last 20 years, and new diagnostic and therapeutic tools are urgently needed to improve the outcomes of this potentially lethal disease.

bladder cancer --- robotic-assisted --- open --- radical cystectomy --- survival --- propensity score --- age --- urothelial carcinoma --- outcome --- anesthesia recovery periods --- cognitive impairment --- gamma-cyclodextrins --- neuromuscular blockade --- robotic radical cystectomy --- glycogen --- clear-cell adenocarcinoma --- urinary bladder --- SEER program database --- female --- intracorporeal neobladder --- outcomes --- robotic --- sex-sparing --- methylation --- biomarkers --- FOXA1 --- GATA3 --- KRT20 --- molecular markers --- mRNA --- muscle-invasive bladder cancer --- PCR --- human epidermal growth factor receptor 2 --- indoleamine 2,3-dioxygenase --- programmed death ligand-1 --- immunotherapy --- nodal disease --- pN1 --- neoadjuvant --- adjuvant --- chemotherapy --- n/a

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

After the long history of screening, it is becoming difficult to find novel compounds from microorganisms and plants anywhere in the world. Until now, more than about 30,000 marine natural products have been reported. However, with the development of marine natural products research, the hit rate of new compounds is also decreasing. Scientists are now turning their attention to the deep sea, where a high hit rate of novel compounds is expected. Many small compounds and peptides from microorganisms and sponges are with therapeutic activity are shown in this book. This Special Issue Book, “Natural Products from the Deep Sea”, should be useful for the screening of novel and useful compounds from nature.

Medicine --- deep sea marine-derived fungus --- Myrothecium sp. --- myrothecol --- nitric oxide (NO) --- antioxidant activity --- macrolactam --- Deep-Sea-Derived Streptomyces --- abiotic formation --- natural product --- antifungal activity --- Thorectandra choanoides --- tryptophan alkaloid --- indoleamine 2,3-dioxygenase --- aplysinopsins --- GNPS molecular network --- cellular signal transduction --- bioactive metabolite --- deep-sea organisms --- anti-inflammatory agent --- anticancer agent --- Mariana Trench --- Micromonospora provocatoris MT25 --- desferrioxamine --- n-acetylglutaminyl glutamine amide --- 1H-15N 2D-NMR --- genomics --- biosynthetic gene clusters --- stress genes --- crustins --- antibacterial peptides --- hydrothermal vent --- anti-Gram-negative bacteria --- Al-crus 3 and Al-crus 7 --- Trichoderma --- harziane diterpenes --- NO inhibition --- thioester-containing benzoate --- deep-sea-derived fungus --- α-glucosidase inhibitory activity --- docking study

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The past decade has seen immunotherapy rise to the forefront of cancer treatment. This Special Issue of Cancers aims to elaborate on the latest developments, cutting-edge technologies, and prospects in cancer immunology and immunotherapy. Seventeen exceptional studies, including original contributions and review articles, written by international scientists and physicians, primarily concerning the fields of tumor biology, cancer immunology, therapeutics, and drug development, comprise the main body of this Special Issue.

Medicine --- NKG2D --- CAR T --- IL-7 --- prostate cancer --- cell therapy --- CD19-CAR-T --- B cell aplasia --- KIR --- PD-1 --- inhibitory CAR --- tumor-infiltrating lymphocytes --- tumor microenvironment --- immunotherapy --- NK cells --- cancer stem cells (CSCs) --- antibody-dependent cellular cytotoxicity (ADCC) --- differentiation --- cytotoxicity --- IFN-γ --- osteoclasts --- MICA/B mAb --- DNA methylation --- RNA methylation --- S-adenosylmethionine (SAM) --- cancer --- innate immunity --- adaptive immunity --- T cells --- m6A --- PD-L1 --- resistance --- immune checkpoints --- cancer vaccine --- combination immunotherapy --- TCR diversity --- organ transplantation --- carcinoma --- epidemiologic studies --- immunosuppression --- CTLA-4 --- Treg cells --- immune checkpoint inhibitors --- CD28 --- antigen-presenting cells --- IL15 --- colon cancer --- melanoma --- uveal --- BAP1 --- anti-PD-1 --- anti-CTLA-4 --- TIL --- classical and endemic Kaposi Sarcoma --- systemic treatment --- multi-state modelling --- treatment free interval --- chemotherapy --- interferon --- triple negative breast cancer --- immunomodulation --- bispecific antibody --- sortase A --- chemo-enzymatic approach --- anti-CD20 antibody --- Fab --- BiFab --- colorectal cancer --- dendritic cells --- Atypical Chemokine Receptor 4 (ACKR4) --- T-cell priming --- immune checkpoint blockade --- primary liver cancer --- kynurenine pathway --- immune evasion --- indoleamine 2,3 dioxygenase 1 --- tryptophan 2,3 dioxygenase 2 --- IDO inhibitor --- antigen presenting cells --- n/a

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The past decade has seen immunotherapy rise to the forefront of cancer treatment. This Special Issue of Cancers aims to elaborate on the latest developments, cutting-edge technologies, and prospects in cancer immunology and immunotherapy. Seventeen exceptional studies, including original contributions and review articles, written by international scientists and physicians, primarily concerning the fields of tumor biology, cancer immunology, therapeutics, and drug development, comprise the main body of this Special Issue.

NKG2D --- CAR T --- IL-7 --- prostate cancer --- cell therapy --- CD19-CAR-T --- B cell aplasia --- KIR --- PD-1 --- inhibitory CAR --- tumor-infiltrating lymphocytes --- tumor microenvironment --- immunotherapy --- NK cells --- cancer stem cells (CSCs) --- antibody-dependent cellular cytotoxicity (ADCC) --- differentiation --- cytotoxicity --- IFN-γ --- osteoclasts --- MICA/B mAb --- DNA methylation --- RNA methylation --- S-adenosylmethionine (SAM) --- cancer --- innate immunity --- adaptive immunity --- T cells --- m6A --- PD-L1 --- resistance --- immune checkpoints --- cancer vaccine --- combination immunotherapy --- TCR diversity --- organ transplantation --- carcinoma --- epidemiologic studies --- immunosuppression --- CTLA-4 --- Treg cells --- immune checkpoint inhibitors --- CD28 --- antigen-presenting cells --- IL15 --- colon cancer --- melanoma --- uveal --- BAP1 --- anti-PD-1 --- anti-CTLA-4 --- TIL --- classical and endemic Kaposi Sarcoma --- systemic treatment --- multi-state modelling --- treatment free interval --- chemotherapy --- interferon --- triple negative breast cancer --- immunomodulation --- bispecific antibody --- sortase A --- chemo-enzymatic approach --- anti-CD20 antibody --- Fab --- BiFab --- colorectal cancer --- dendritic cells --- Atypical Chemokine Receptor 4 (ACKR4) --- T-cell priming --- immune checkpoint blockade --- primary liver cancer --- kynurenine pathway --- immune evasion --- indoleamine 2,3 dioxygenase 1 --- tryptophan 2,3 dioxygenase 2 --- IDO inhibitor --- antigen presenting cells --- n/a